VITAMIN D IN THE COVID-19 PREVENTION AND TREATMENT: EMERGING EVIDENCE

A. D’Avolio1, G. Isaia1,2 on behalf of COVID-Vitamin D Study Group, Accademia di Medicina di Torino

1 Department of Medical Sciences, University of Turin, Turin, Italy
2 Accademia di Medicina di Torino, Turin, Italy
Antonio D’Avolio and Giancarlo Isaia contributed equally to this work.

E-mail: antonio.davolio@unito.it
Doi: 10.36118/pharmadvances.2021.01

SUMMARY
The significantly higher incidence of COVID-19 on mortality and morbidity observed in the northern Italian regions as compared to the southern ones, could be partly explained by geographic variations of the prevalence of vitamin D deficiency. The present opinion paper discusses this hypothesis. The immunomodulatory effects of vitamin D have been widely established and its benefits on viral and bacterial replication have been attributed to its ability to modulate gene expression by activating the vitamin D receptor in many target cells, including immune cells, and by promoting the expression of antimicrobial peptides such as cathelicidins and beta-defensins, which are also endowed with antiviral and immunomodulatory properties. Recently, following the onset of the COVID-19 pandemic situation, many studies have shown a high prevalence of very low levels of vitamin D in patients with severe manifestations of the disease, and that high dose vitamin D administration appeared able to favourably modify the evolution of the infection. Although these studies, mainly based on cross-sectional analyses and small-scale randomized clinical studies, could not provide a definitive proof of a cause-effect relationship, it is possible to suggest that hypovitaminosis D might be considered “guilty by association” as one of the factors able to worsen the pandemic spread and its clinical impact.

INTRODUCTION
Last year has shown that COVID-19 pandemic has specific characteristics, but scientific research, mostly geared towards development of specific antibodies and vaccines to contrast the virus, has not provided enough knowledge about other alternative tools to fight the disease. Little is known about the pathophysiological characteristics of the disease, the mechanisms that favour the infection of the human species or about the molecular targets to develop pharmacological treatment. Due to these unaddressed issues, new protective strategies are very hard to propose and validate and therefore, they are currently limited to the undisputable and fundamental measures of physical distance and individual hygiene.

© 2021 The Italian Society of Pharmacology (SIF). Published by EDRA SPA. All rights reserved
In Italy, one of the most heavily afflicted European countries, significant differences in mortality and morbidity by COVID-19, have been observed between northern and southern regions, with a greater impact in northern regions, at least during the first wave. Moreover, the disease has proven to be particularly aggressive in older people (78.4% of the dead patients aged between 60 and 89 years), notably in nursing home residents (Sars-cov-2 decessi Italia). In the past, the important role of solar radiation, empirically deducted from latitude, was proven in the case of the 1918-1919 pandemic influenza in the USA (1).

For these reasons, hypovitaminosis D, mainly due to lack of solar UV radiations and more frequent in aging population and resulted, also for diet, highest during the winter and spring, when 25(OH)D concentrations < 25, < 40, and < 75 nmol/L were found in 15.5%, 46.6%, and 87.1% of participants, respectively (2): for these reasons it has been assumed to be one possible additional causal determinant of the pandemic (3). The link between COVID-19 and hypovitaminosis D has also been suggested by the results of our recent ecological-statistical study (4) performed in collaboration with several Italian universities and environmental institutions, in which we examined the spatial distribution of the outbreak in Italy during the first-wave period (February-May 2020); our country is the ideal test area to explore a correlation between the clinical outcomes of the pandemic and the geographical distribution of solar UV irradiance, due to its long extension, ranging from latitudes higher than 46° N in Trentino-South Tyrol, to less than 36° N in Sicily: it has been assessed the levels of ultraviolet rays (UV) at the Earth’s surface and compared it with the number of dead and affected patients. The investigation proved that regional COVID-19 deaths and infections had a very significant correlation with the intensity of solar UV at the Earth’s surface measured in each region by satellite and soil detection (5).

### RELATIONSHIP BETWEEN VITAMIN D AND COVID-19 PATHOPHYSIOLOGY AND COMPLICATIONS

A large number of papers recently published have considered the link between COVID-19 and vitamin D, both with retrospective investigations (6) and meta-analysis (7). In general, the presence of hypovitaminosis D of patients with COVID-19, especially in severe cases (more than 50% of the cases) (8) and higher associated mortality, with odd ratio of 1.82 (5) and 3.87 (9), has been confirmed. In a study including either asymptomatic or severely ill COVID-19 patients requiring Intensive Care Unit (ICU) admission, and adopting the cut-off concentration level of serum 25-hydroxyvitamin D [25(OH)D] < 30 ng/ml for define vitamin D deficiency, its prevalence was 31.86% and 96.82% respectively (10).

Although the presence of a “reverse causality” cannot still be ruled out, several pathophysiological mechanisms explaining the possible influence of hypovitaminosis D on COVID-19 have been brought forward (11):

- **a)** it is well known that the active metabolite of vitamin D, calcitriol \([1,25(OH)_{2}D_{3}]\), exerts many different biological effects: its specific receptor (VDR) is present in many tissues as well as white blood cells, where it mediates the immune response (12). Particularly, intracellular synthesis of calcitriol by monocytes/macrophages promotes the expression of the antimicrobial proteins cathelicidins and beta-defensins, and enhances intracellular killing of endocytosed microbes in innate immunity. Moreover, calcitriol exerts an inhibitory, anti-inflammatory effect, preventing multiple organ damage in adaptive immunity (13). Thus, it suppresses the progression of inflammation by reducing the generation of pro-inflammatory cytokines such as IL-12, IL-2, and interferon gamma (IFN-\(\gamma\)), involved in the T helper type 1 response, and IL-17, involved in the T helper type 17 response, and accompanying the decrease of acute inflammation mediators such as TNF\(\alpha\), IL-6, and IL-8 (14, 15).
b) Angiotensin II (Ang II) is a natural peptide hormone which play a pivotal role in the renin-angiotensin-aldosterone system and Angiotensin Converting Enzyme 2 (ACE2) directly catalyzes the conversion of Ang II to angiotensin-(1-7), thereby lowering its levels. COVID-19 infection appears to downregulate ACE2, which in turn could lead to excessive accumulation of Ang II which exerts pro-inflammatory properties. High levels of Ang II may cause Acute Respiratory Distress Syndrome (ARDS), myocarditis, or cardiac injury, and, interestingly, vitamin D supplementation was shown to prevent Ang II accumulation and to decrease its proinflammatory activity by suppressing the release of renin in patients infected with COVID-19 (16).

c) It is also plausible that a reduced availability of 7-dehydrocholesterol - the chemical precursor of vitamin D found in large amounts in keratinocytes - led to a reduction in the levels of its metabolite vitamin D as a consequence of the marked reduction of cholesterol observed in patients with moderate or severe forms of COVID-19 (17).

CLINICAL REPORTS

Recent clinical contributions provide interesting suggestions for low-cost interventions, and potentially useful to the entire elderly population that in Italy (18) is largely vitamin D deficient, likely due to the lack of vitamin D food fortification.

To build a proposal, we have selected some papers regarding clinical trials, supporting the usefulness of vitamin D administration (mainly cholecalciferol) for both prevention and treatment of COVID-19 patients:

1) in a randomised study of 76 symptomatic COVID-19 patients, the percentage of subjects for whom intensive care unit admission was required was 2% in the group treated with high-dose calcifediol and 50% in untreated patients (19).

2) A retrospective study of over 190,000 patients evidenced a significant inverse correlation between SARS-CoV-2 positivity rates and circulating levels of vitamin D (20).

3) In 77 elderly subjects hospitalized for COVID-19, the probability of survival estimated was significantly and positively related to the administration of cholecalciferol, taken in the previous year at the dose of 50,000 IU per month, or 80,000 IU for 2-3 months, or 80,000 IU at the time of diagnosis (21).

4) In PCR-positive patients for SARS-CoV-2, vitamin D levels were significantly lower ($p = 0.004$) than in negative PCR ones (22): these findings were confirmed by other works in terms of increased viral clearance and healing for those with higher blood vitamin D levels.

5) In a clinical trial on 40 asymptomatic or oligosymptomatic patients, disease negativization in 62.5% of patients treated with high-dose cholecalciferol (60,000 IU/die for 7 days) as compared to 20.8% of patients in the control group was observed (23).

COMMENTS

Based on the results of these and other studies, we can make the following remarks:

1) although further controlled and randomized studies are required, vitamin D appears more effective against COVID-19 (both for negativity rate and for benign evolution of the disease) when administered for preventive purpose, particularly in fragile and institutionalised elderly subjects (24). There is pathophysiologic rationale for exploring the use of vitamin D in this global pandemic, despite supported by early reports from international groups (25).

2) The minimum plasma target level of 25(OH)D to be achieved for prevention would be 40 ng/ml (26). To reach this target value, high cholecalciferol doses - up to 4,000 IU per day, depending on patient baseline plasma 25(OH)D levels - have to be administered (27).

3) Randomized studies indicate the usefulness of a single bolus administration of 80,000
IU of cholecalciferol (21, 23) or calcifediol (0.532 mg on the first day, 0.266 mg on the third and seventh days and then once a week) (19) or 60,000 UI of cholecalciferol for seven days with the aim of achieving a serum 25(OH)D concentration of 50 ng/ml (23, 25).

Despite these and other data, vitamin D supplementation as a prevention strategy against COVID-19 is not widely used because of the lack of randomized placebo-controlled trials. However, unlike other vitamins or supplements, evidence on the usefulness of vitamin D in the settings of prevention and treatment of COVID-19 is gradually emerging. A recent review suggested that vitamin D supplementation might play a role in the prevention and/or treatment to SARS-CoV-2 infection, disease, by modulating the immune response to the virus both in the adult and paediatric population (28). Instead, in the UK supplementation of vitamin D to 2.7 million people at risk of COVID-19 (the elderly, the black population or the residents in nursing homes) was recently disposed and defined as a “low-cost, zero-risk, potentially highly effective action” (https://www.theguardian.com/world/2020/nov/14/covid-uk-government-requests-guidance-on-vitamin-d-use): the subsequent debate led NICE expressed some doubts (www.nice.org.uk/guidance/ng187): in particular NICE state that there is not enough evidence to support taking vitamin D solely to prevent or treat COVID-19. Nevertheless, the Royal Society of London to state that it “…seems nothing to lose and potentially much to gain”.

CONCLUSIONS
In conclusion, although the usefulness of vitamin D in the prevention and treatment of COVID-19 is not yet fully defined (not even for SARS-CoV-2 variants), we believe that that there is a great need for further research in this field that should be taken into account by the public health Institutions, to possibly promote:

a) activation of a consensus conference or/and a randomized and controlled clinical trial on the therapeutic efficacy of vitamin D in symptomatic or oligosymptomatic COVID-19 patients, according to one of the following schedules of vitamin D administration:
- oral cholecalciferol 60,000 IU per day for seven consecutive days;
- single cholecalciferol administration (80,000 IU) in aged patients;
- oral calcifediol 0.532 mg on day 1 and 0.266 mg on days 3, and 7 once weekly afterwards.

b) Preventive administration of oral cholecalciferol (up to 4,000 IU per day) to subjects at higher risk of contagion and disease severity (frail elderly, obese subjects, health care professionals, close contacts and relatives of infected patients, subject from closed communities), especially during the cold period; it is important noting that in this context vitamin D non-hydroxylated compounds are not associated with significant side effects (29). Anyway, vitamin D supplementation would be helpful to correct vitamin D deficiency - which is also regarded as a global pandemic, especially during the winter months and irrespective of SARS-CoV-2 infection.

c) The organization and promotion of public health campaigns aimed to raise awareness of both positive and negative effects of the solar radiation and also by fostering active measures to increase the individual serum vitamin D levels, either through pharmacological supplementation (carried out under medical supervision) or through the consumption of vitamin-D-rich foods. This is particularly true for the elderly, since: (i) in general, they seldom set themselves to the sun and their skin has a lower efficiency in the synthesis of vitamin D compared to young people (30); (ii), they do not gladly eat food containing vitamin D, such as fat cheese, butter, mushroom, some fish; (iii) the assumption of food fortified with vitamin D is not very diffused in Italy.
CONFLICT OF INTERESTS

The authors and the members of “COVID-Vitamin D Study Group, Accademia di Medicina di Torino”** declare that they have no conflict of interests to disclose in the specific field covered by this paper.

* D. Agnusdei (Siena), P. M. Allegri (Padua), F. Altruda (Turin), A. Angeli (Turin), P. Arese (Turin), M. Astegiano (Turin), A. Aversa (Catanzaro), M. Barbagallo (Palermo), M. Baroni (Perugia), A. Bargoni (Turin), C. Bertino (Turin), L. Biancone (Turin), A. Biolcati (Novara), E. Bologna (Alba - CN), A. Bosia (Turin), G. Bruno (Pavia), C. Bucca (Turin), E. Cacace (Cagliari), R. Caccialanza (Pavia), T. Cammarota (Turin), V. Camozzi (Padua), C. Campagnoli (Turin), M. Campogrande (Turin), M. Caprio (Rome), A. Catalano (Viterbo), R. Cavallo (Turin), P. Cavallo Perin (Turin), C. Ceruti (Turin), A. Cester (Venezia), A. Chio (Turin), A. Ciampolillo (Bari), A. Cicero (Bologna), C. Cisari (Novara), A. Colao (Napoli), A. Comandone (Turin), L. Cordero di Montezemolo (Turin), F. Crapanzano (Agrigento), S. Cristallini (Perugia), F. D’Ambrosio (Ancona), G. D’Avola (Acireale, CT), C. Del Prete (Lucano, CH), G. De Renzi (Orbassano, Turin), C. de Sanctis (Turin), U. Dianzani (Novara), F. Di Carlo (Turin), O. Di Munno (Pisa), F. Di Salvo (Palermo), F. Di Stefano (Omegna, VB), M. Di Stefano (Turin), L. Domínguez (Palermo), P. Donadio (Turin), F. Dotta (Siena), A. Fabbrini (Rome), S. Falcone (Rome), R. Fantozzi (Turin), E. Favaro (Turin), R. Ferracini (Genova), E. Ferretti (Rome), M. T. Fierro (Turin), E. Finocchiaro (Turin), S. Flangini (Legnago, VR), C. Foresta (Padua), G. Fornero (Turin), G. Forni (Turin), C. M. Francucci (Ancona), R. Fruttero (Turin), E. Fusaro (Turin), A. Gaetini (Turin), L. Gallelli (Catanzaro), M. Alessandra Gardini (Rome), G. Gasparri (Turin), A. Gaudio (Catania), G. Giacchetti (Ancona), S. Gonnelli (Siena), M. Grano (Bari), M. Infante (Rome), G. Isaia (Turin), C. Laurentaci (Matera), G. L. Mauro (Palermo), P. Limone (Turin), R. Liuzzi (Monza), S. Livigni (Turin), L. Maffi (Turin), S. Maggi (Padua), M. Maggiorotti (Rome), F. Malavasi (Turin), M. Marangella (Turin), N. Marchionni (Florence), A. Massè (Turin), A. Mattiota (San Maurizio Canavese, Turin), P. Mecocci (Perugia), E. Medico (Turin), S. Migliaccio (Rome), M. Alessandro Minetto (Turin), G. Minisola (Rome), V. Modena (Turin), E. Montanari (Bologna), F. Monzani (Pisa), F. Morabito (Alba, CN), M. Morello (Rome), E. Morini (Messenia), R. Mutani (Turin), M. Nano (Turin), F. Orlandi (Turin), V. Orte (Rome), A. Palma (Melegnano, Milan), L. M. Pernigotti (Turin), A. Piazza (Turin), G. Pietrocola (Pavia), L. Pietrogrande (Milano), G. Poli (Turin), F. Poppiglia (Turin), P. Presbitero (Rozzano, Milan), P. Quaglini (Turin), U. Ramenghi (Turin), Z. Ranieri (Milano), D. Regge (Turin), U. Riba (Turin), G. R. Riccardi (Ancona), G. Ricevuti (Pavia), S. Rindi (Pavia), D. Roccadello (Turin), A. Romeo (Siracusa), V. Ronconi (Jesi, AN), R. Rosina (Turin), C. Ruggiero (Perugia), G. Saglio (Turin), S. Salomone (Palermo), A. Sapino (Turin), L. Sartori (Padua), F. Scarnati (Taverna di Montalto, CS), F. Scarpina (Turin), G. Segoloni (Turin), L. Massimino Sena (Turin), U. Senin (Perugia), M. Sfrappini (Ancona), E. Shahini (Candiolo, Turin), D. Silengo (Turin), A. Silvestri (Cuneo), G. Spera (Rome), P. Stratta (Novara), L. Sutera (Palermo), L. Tafaro (Rome), G. Tanturri (Turin), F. M. Ulivieri (Milan), L. Vaira (Rivoli, Turin), R. Vettor (Padua), P. Villaba Fabiano (Frosinone), E. Villari (Turin), E. Viora (Turin), U. Vitolo (Candiolo, Turin).

REFERENCES

2. Hyppönen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide
Vitamin D in the COVID-19 prevention and treatment: emerging evidence


